vs
如新（NUS）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
如新的季度营收约是Orthofix Medical Inc.的1.5倍（$320.6M vs $219.9M），如新净利率更高（0.6% vs -1.0%，领先1.6%），Orthofix Medical Inc.同比增速更快（2.0% vs -12.0%），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs -14.5%）
如新企业集团是一家美国多层次直销企业，主打研发并销售个人护理产品与营养膳食补充产品，旗下拥有Nu Skin及Pharmanex两大品牌，目前已在全球54个市场开展业务，依托约120万独立销售代表的销售网络覆盖全球市场。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
NUS vs OFIX — 直观对比
营收规模更大
NUS
是对方的1.5倍
$219.9M
营收增速更快
OFIX
高出14.0%
-12.0%
净利率更高
NUS
高出1.6%
-1.0%
两年增速更快
OFIX
近两年复合增速
-14.5%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $320.6M | $219.9M |
| 净利润 | $1.8M | $-2.2M |
| 毛利率 | 66.9% | 71.1% |
| 营业利润率 | 34.4% | 0.2% |
| 净利率 | 0.6% | -1.0% |
| 营收同比 | -12.0% | 2.0% |
| 净利润同比 | — | 92.4% |
| 每股收益（稀释后） | $0.04 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NUSOFIX
| Q1 26 | $320.6M | — | ||
| Q4 25 | $370.3M | $219.9M | ||
| Q3 25 | $364.2M | $205.6M | ||
| Q2 25 | $386.1M | $203.1M | ||
| Q1 25 | $364.5M | $193.6M | ||
| Q4 24 | $445.6M | $215.7M | ||
| Q3 24 | $430.1M | $196.6M | ||
| Q2 24 | $439.1M | $198.6M |
净利润NUSOFIX
| Q1 26 | $1.8M | — | ||
| Q4 25 | $14.5M | $-2.2M | ||
| Q3 25 | $17.1M | $-22.8M | ||
| Q2 25 | $21.1M | $-14.1M | ||
| Q1 25 | $107.5M | $-53.1M | ||
| Q4 24 | $-36.1M | $-29.1M | ||
| Q3 24 | $8.3M | $-27.4M | ||
| Q2 24 | $-118.3M | $-33.4M |
毛利率NUSOFIX
| Q1 26 | 66.9% | — | ||
| Q4 25 | 70.7% | 71.1% | ||
| Q3 25 | 70.5% | 72.2% | ||
| Q2 25 | 68.8% | 68.7% | ||
| Q1 25 | 67.8% | 62.8% | ||
| Q4 24 | 62.7% | 69.0% | ||
| Q3 24 | 70.1% | 68.7% | ||
| Q2 24 | 70.0% | 67.8% |
营业利润率NUSOFIX
| Q1 26 | 34.4% | — | ||
| Q4 25 | 6.3% | 0.2% | ||
| Q3 25 | 5.9% | -8.3% | ||
| Q2 25 | 8.0% | -7.9% | ||
| Q1 25 | -2.7% | -25.2% | ||
| Q4 24 | -11.9% | -5.3% | ||
| Q3 24 | 4.2% | -9.6% | ||
| Q2 24 | -28.6% | -12.5% |
净利率NUSOFIX
| Q1 26 | 0.6% | — | ||
| Q4 25 | 3.9% | -1.0% | ||
| Q3 25 | 4.7% | -11.1% | ||
| Q2 25 | 5.5% | -6.9% | ||
| Q1 25 | 29.5% | -27.4% | ||
| Q4 24 | -8.1% | -13.5% | ||
| Q3 24 | 1.9% | -13.9% | ||
| Q2 24 | -26.9% | -16.8% |
每股收益（稀释后）NUSOFIX
| Q1 26 | $0.04 | — | ||
| Q4 25 | $0.27 | $-0.05 | ||
| Q3 25 | $0.34 | $-0.57 | ||
| Q2 25 | $0.43 | $-0.36 | ||
| Q1 25 | $2.14 | $-1.35 | ||
| Q4 24 | $-0.73 | $-0.76 | ||
| Q3 24 | $0.17 | $-0.71 | ||
| Q2 24 | $-2.38 | $-0.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $198.7M | $82.0M |
| 总债务越低越好 | $223.6M | — |
| 股东权益账面价值 | $794.1M | $450.0M |
| 总资产 | $1.4B | $850.6M |
| 负债/权益比越低杠杆越低 | 0.28× | — |
8季度趋势，按日历期对齐
现金及短期投资NUSOFIX
| Q1 26 | $198.7M | — | ||
| Q4 25 | $239.8M | $82.0M | ||
| Q3 25 | $253.0M | $62.9M | ||
| Q2 25 | $265.4M | $65.6M | ||
| Q1 25 | $213.6M | $58.0M | ||
| Q4 24 | $198.0M | $83.2M | ||
| Q3 24 | $237.8M | $30.1M | ||
| Q2 24 | $232.9M | $26.4M |
总债务NUSOFIX
| Q1 26 | $223.6M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M |
股东权益NUSOFIX
| Q1 26 | $794.1M | — | ||
| Q4 25 | $805.2M | $450.0M | ||
| Q3 25 | $799.8M | $442.5M | ||
| Q2 25 | $787.8M | $458.3M | ||
| Q1 25 | $754.0M | $458.3M | ||
| Q4 24 | $651.5M | $503.1M | ||
| Q3 24 | $706.9M | $525.9M | ||
| Q2 24 | $686.2M | $546.0M |
总资产NUSOFIX
| Q1 26 | $1.4B | — | ||
| Q4 25 | $1.4B | $850.6M | ||
| Q3 25 | $1.4B | $832.6M | ||
| Q2 25 | $1.4B | $837.2M | ||
| Q1 25 | $1.4B | $823.1M | ||
| Q4 24 | $1.5B | $893.3M | ||
| Q3 24 | $1.6B | $867.9M | ||
| Q2 24 | $1.6B | $882.0M |
负债/权益比NUSOFIX
| Q1 26 | 0.28× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $27.7M |
| 自由现金流经营现金流 - 资本支出 | — | $16.8M |
| 自由现金流率自由现金流/营收 | — | 7.6% |
| 资本支出强度资本支出/营收 | — | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-1.3M |
8季度趋势，按日历期对齐
经营现金流NUSOFIX
| Q1 26 | — | — | ||
| Q4 25 | $16.6M | $27.7M | ||
| Q3 25 | $27.5M | $12.4M | ||
| Q2 25 | $35.8M | $11.6M | ||
| Q1 25 | $389.0K | $-18.4M | ||
| Q4 24 | $25.8M | $23.7M | ||
| Q3 24 | $31.4M | $11.7M | ||
| Q2 24 | $51.2M | $9.0M |
自由现金流NUSOFIX
| Q1 26 | — | — | ||
| Q4 25 | $5.9M | $16.8M | ||
| Q3 25 | $17.6M | $2.5M | ||
| Q2 25 | $35.8M | $4.5M | ||
| Q1 25 | $-13.2M | $-25.1M | ||
| Q4 24 | $13.2M | $15.2M | ||
| Q3 24 | $22.8M | $6.3M | ||
| Q2 24 | $43.1M | $-360.0K |
自由现金流率NUSOFIX
| Q1 26 | — | — | ||
| Q4 25 | 1.6% | 7.6% | ||
| Q3 25 | 4.8% | 1.2% | ||
| Q2 25 | 9.3% | 2.2% | ||
| Q1 25 | -3.6% | -13.0% | ||
| Q4 24 | 3.0% | 7.0% | ||
| Q3 24 | 5.3% | 3.2% | ||
| Q2 24 | 9.8% | -0.2% |
资本支出强度NUSOFIX
| Q1 26 | — | — | ||
| Q4 25 | 2.9% | 4.9% | ||
| Q3 25 | 2.7% | 4.8% | ||
| Q2 25 | 0.0% | 3.5% | ||
| Q1 25 | 3.7% | 3.5% | ||
| Q4 24 | 2.8% | 4.0% | ||
| Q3 24 | 2.0% | 2.7% | ||
| Q2 24 | 1.9% | 4.7% |
现金转化率NUSOFIX
| Q1 26 | — | — | ||
| Q4 25 | 1.15× | — | ||
| Q3 25 | 1.61× | — | ||
| Q2 25 | 1.69× | — | ||
| Q1 25 | 0.00× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.79× | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NUS
暂无分部数据
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
